ARQT
Arcutis Biotherapeutics Inc
NASDAQ: ARQT · HEALTHCARE · BIOTECHNOLOGY
$23.22
+3.80% today
Updated 2026-04-30
Market cap
$2.91B
P/E ratio
—
P/S ratio
7.75x
EPS (TTM)
$-0.13
Dividend yield
—
52W range
$12 – $32
Volume
1.3M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A5.8
Quality
C+3.0
Profitability
D6.7
Valuation
B4/9
Piotroski F-Score
Moderate
-2.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$34.75
+49.66%
12-Month target
—
—
Intrinsic (DCF)
$134.09
Margin of safety
+80.17%
2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $26.18M — positive
+ Revenue growth 81.50% QoQ
+ 80.17% below intrinsic value
Risks
- Altman Z -2.08 — distress zone
- Thin margins at -4.29%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.69M | $59.61M | $196.54M | $376.07M | $376.07M |
| Net income | $-311.46M | $-262.14M | $-140.04M | $-16.14M | $17.39M |
| EPS | — | — | — | — | $-0.13 |
| Free cash flow | $-281.00M | $-247.49M | $-112.30M | $-6.31M | $26.18M |
| Profit margin | -8,449.76% | -439.79% | -71.25% | -4.29% | -4.29% |
Peer comparison
Smart narrative
Arcutis Biotherapeutics Inc trades at $23.22. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -2.08, it sits in the distress. TTM revenue stands at $376.07M. with profit margins at -4.29%. Our DCF model estimates intrinsic value at $134.09.
Frequently asked questions
What is Arcutis Biotherapeutics Inc's stock price?
Arcutis Biotherapeutics Inc (ARQT) trades at $23.22.
Is Arcutis Biotherapeutics Inc overvalued?
Smart Value Score 36/100 (Grade D, Sell). DCF value $134.09.
What is the price target of Arcutis Biotherapeutics Inc (ARQT)?
The analyst target price is $34.75, representing +49.7% upside from the current price of $23.22.
What is the intrinsic value of Arcutis Biotherapeutics Inc (ARQT)?
Based on our DCF model, intrinsic value is $134.09, a +80.2% margin of safety versus $23.22.
What is Arcutis Biotherapeutics Inc's revenue?
TTM revenue is $376.07M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-2.08 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.75x
ROE-9.30%
Beta1.77
50D MA$24.10
200D MA$22.73
Shares out0.13B
Float0.09B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—